Τίτλος:
Resistance to activated protein C and FV Leiden mutation in patients
with a history of acute myocardial infarction or primary hypertension
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
This study was designed to investigate both resistance to activated
protein C (APC-R) and the factor FV Q506 mutation incidence in patients
with a history of acute myocardial infarction (AMI) and patients with
primary hypertension (PH), a highrisk group for arterial thrombosis.
Eighty patients with a history of AMI (group A), 160 patients with a
history of PH (group B), and 124 age-matched controls without arterial
disease (group C) were studied. APC-R was determined using the Coatest
APC Resistance Kit of Chromagenix, Sweden. The prevalence of the FV Q506
mutation was estimated by DNA analysis (Bertina method). The prevalence
of the FV Q506 mutation was 20%, 13.75%, and 8% in groups A, B, and
C, respectively (A v C P = .0466). The prevalence of APC-R was 47.5% in
group A v 13% in group C (P < .0001) and 36.25% in group B v13% in
group C (P < .0001). The response to activated protein C expressed as
mean value +/- SD was 2.05 +/- 0.33 in group A v 2.56 +/- 0.46 in group
C (P < .05) and 2 +/- 0.22 in group B v 2.56 +/- 0.46 in group C (P <
.05). These findings suggest that patients with a history of AMI or PH
have a significantly increased incidence of both APC-R and FV Q506
mutation compared with the control group. These findings support the
hypothesis that these anticoagulant defects may be risk factors for
arterial thrombosis. (C) 2000 American Journal of Hypertension, Ltd.
Συγγραφείς:
Makris, TK
Krespi, PG
Hatzizacharias, AN
Gialeraki, AE and
Anastasiadis, G
Triposkiadis, FK
Mandalaki, T
Kyriakidis, MK
Περιοδικό:
American Journal of Hypertension
Εκδότης:
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
Λέξεις-κλειδιά:
myocardial infarction; hypertension; genetics; thrombosis
DOI:
10.1016/S0895-7061(99)00140-5
